X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: In need of ‘calcium sandoz’ - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Dec 8, 2000

    Novartis: In need of ‘calcium sandoz’

    Novartis held an analyst meet yesterday to apprise investors of the latest developments after the hive off the agri business operations. The management announced a takeover of the Ciba CKD, a joint venture with a Korean company, elaborated on the realignment of its ophthalmic business and expressed its intent to divest the remaining portion of its Goregaon (a Mumbai suburb) property.

    Ciba CKD was a joint venture between Novartis India and Chong Kuon Dang (Korea) for the manufacture of rifampicin, an anti–TB bulk drug. The company bought out the Korean partner’s stake at a price of Rs 7.48 per share. The reasoning for this buyout was the fact that anti–TB is an important therapeutic area for the company (it contributes almost 8% to the company’s turnover) and the management felt that the collaboration was not working out. The management, however, was not willing to specify whether it would merge Ciba CKD with Novartis India in the future.

    As far as the divestment of the property is concerned, the management has appointed a real estate consultant Knight Frank to manage the sale. In the current year, the company gave the development rights for a part of the property to Kingston Properties for a price of Rs 66 m. The management did clarify that a part of the property (297,000 square metres of surface area) does face various reservations being in a non–industrial zone and certain rights belong to Ciba Specialties, which was also a part of the erstwhile Hindustan Ciba Geigy.

    As far as the realignment of the ophthalmic business is concerned, the business now forms a part of the pharmaceutical business under Mr. Ranjit Shahani. This business, was earlier clubbed with the contact lens business, and was part of Ciba Vision.

    As far as the pharmaceutical business goes, the company has plans to introduce four brands Coartem (an anti–malarial), Zometa (anti–cancer), Visodyne (a sight saving product) and Miacalcic (osteoporosis). However, the company’s top brand Voveran (an anti–inflammatory), which contributed almost 18% to Novartis’ turnover, seems to be facing a slowdown, although the management denies it. It’s immuno–suppressant brand Sandimune (which contributes over 12% to Novartis’ turnover) has also been slapped with a 15% import duty, which has raised its costs by 40%. Overall, FY01 is likely to be tough one for Novartis as far as topline growth is concerned and this explains the relatively lower earnings multiple (23X FY01 earnings) vis-à-vis the other MNC pharma companies.

     

     

    Equitymaster requests your view! Post a comment on "Novartis: In need of ‘calcium sandoz’". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    NOVARTIS SHARE PRICE


    Aug 22, 2017 11:06 AM

    TRACK NOVARTIS

    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    NOVARTIS 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE NOVARTIS WITH

    MARKET STATS